PDX models are created by implanting tumor tissues directly from cancer patients into immunodeficient mice. These models retain the genetic, histological, and molecular characteristics of the original patient tumors, including tumor heterogeneity and drug response profiles. As a result, PDX models serve as highly predictive in vivo platforms for preclinical drug evaluation, biomarker discovery, and personalized medicine research.

Through collaboration with Gempharmatech, we provide > 160 types of clinically relevant PDX models across a wide range of tumor types, enabling researchers to bridge the gap between laboratory findings and clinical outcomes with high translational fidelity.

Below is a selection of available PDX models: